Quick Answer
LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported Operating Income Loss of -$5.11 million for the year ending 2025.
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. showed a decrease of -43.0% in Operating Income Loss from 2024 to 2025.
- This data is from LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2012: -$591.9 thousand | Q2 2012: -$400.0 thousand | Q3 2012: -$838.2 thousand | Q1 2013: -$333.9 thousand | Q2 2013: -$368.8 thousand | Q3 2013: -$313.1 thousand | Q1 2014: -$715.8 thousand | Q2 2014: -$517.3 thousand | Q3 2014: -$501.4 thousand | Q1 2015: -$752.2 thousand | Q2 2015: -$500.7 thousand | Q3 2015: -$779.7 thousand | Q1 2016: -$416.6 thousand | Q2 2016: -$555.0 thousand | Q3 2016: -$647.1 thousand | Q1 2017: -$602.6 thousand | Q2 2017: -$292.9 thousand | Q3 2017: -$463.2 thousand | Q1 2018: -$379.8 thousand | Q2 2018: -$371.9 thousand | Q3 2018: -$1.03 million | Q1 2019: -$438.7 thousand | Q2 2019: -$627.9 thousand | Q3 2019: -$1.09 million | Q1 2020: -$387.2 thousand | Q2 2020: -$373.4 thousand | Q3 2020: -$1.60 million | Q1 2021: -$1.73 million | Q2 2021: -$1.73 million | Q3 2021: -$1.24 million | Q1 2022: -$1.65 million | Q2 2022: -$1.55 million | Q3 2022: -$1.48 million | Q1 2023: -$1.37 million | Q2 2023: -$1.67 million | Q3 2023: -$1.02 million | Q1 2024: -$966.9 thousand | Q2 2024: -$1.01 million | Q3 2024: -$983.3 thousand | Q1 2025: -$706.9 thousand | Q2 2025: -$774.8 thousand | Q3 2025: -$1.80 million.
- Over the full 16 years of available data (2010 to 2025), LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Operating Income Loss has declined by 479.3%.
- Historical annual values: Fiscal year 2025: -$5.11 million | Fiscal year 2024: -$3.57 million | Fiscal year 2023: -$5.09 million | Fiscal year 2022: -$6.31 million | Fiscal year 2021: -$6.72 million | Fiscal year 2020: -$3.27 million | Fiscal year 2019: -$2.49 million | Fiscal year 2018: -$2.14 million | Fiscal year 2017: -$1.81 million | Fiscal year 2016: -$2.13 million | Fiscal year 2015: -$2.65 million | Fiscal year 2014: -$2.40 million | Fiscal year 2013: -$1.37 million | Fiscal year 2012: -$2.11 million | Fiscal year 2011: -$1.87 million | Fiscal year 2010: -$881.7 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: